Pembroke Management LTD Trimmed By $3.68 Million Its Mgp Ingredients (MGPI) Position; Venbio Select Advisor Decreased Its Biocryst Pharmaceuticals (BCRX) Position

February 24, 2018 - By Darrin Black

Venbio Select Advisor Llc decreased Biocryst Pharmaceuticals Inc (BCRX) stake by 8.96% reported in 2017Q3 SEC filing. Venbio Select Advisor Llc sold 175,000 shares as Biocryst Pharmaceuticals Inc (BCRX)’s stock declined 16.46%. The Venbio Select Advisor Llc holds 1.78M shares with $9.32M value, down from 1.95 million last quarter. Biocryst Pharmaceuticals Inc now has $494.13 million valuation. The stock increased 4.58% or $0.22 during the last trading session, reaching $5.02. About 870,553 shares traded. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has risen 75.08% since February 24, 2017 and is uptrending. It has outperformed by 58.38% the S&P500.

Pembroke Management Ltd decreased Mgp Ingredients Inc (MGPI) stake by 31.7% reported in 2017Q3 SEC filing. Pembroke Management Ltd sold 61,400 shares as Mgp Ingredients Inc (MGPI)’s stock rose 22.02%. The Pembroke Management Ltd holds 132,265 shares with $8.02M value, down from 193,665 last quarter. Mgp Ingredients Inc now has $1.45 billion valuation. The stock increased 2.93% or $2.47 during the last trading session, reaching $86.65. About 114,622 shares traded. MGP Ingredients, Inc. (NASDAQ:MGPI) has risen 102.52% since February 24, 2017 and is uptrending. It has outperformed by 85.82% the S&P500.




Venbio Select Advisor Llc increased Ascendis Pharma stake by 645,200 shares to 1.64 million valued at $59.31M in 2017Q3. It also upped Pacira Pharmaceuticals Inc (NASDAQ:PCRX) stake by 845,642 shares and now owns 1.31 million shares. Teligent Inc was raised too.

Investors sentiment increased to 1.69 in Q3 2017. Its up 0.01, from 1.68 in 2017Q2. It increased, as 12 investors sold BCRX shares while 24 reduced holdings. 28 funds opened positions while 33 raised stakes. 79.80 million shares or 20.47% more from 66.24 million shares in 2017Q2 were reported. 56,000 are owned by State Of Wisconsin Invest Board. Oberweis Asset has 17,100 shares. Pacad Investment Ltd owns 22,200 shares or 0.03% of their US portfolio. Northern Corp reported 1.01M shares. Northeast Financial Consultants accumulated 20,000 shares. Deutsche Bank Ag reported 254,519 shares. New York State Common Retirement Fund reported 83,800 shares or 0% of all its holdings. Gsa Capital Prtn Limited Liability Partnership reported 13,086 shares or 0% of all its holdings. Winch Advisory Svcs Ltd Liability owns 200 shares or 0% of their US portfolio. Moreover, D E Shaw Company has 0.01% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 1.49M shares. Citigroup Inc holds 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) or 28,255 shares. Retail Bank Of Ny Mellon Corporation has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Sei has 588 shares. Moreover, Gru One Trading Ltd Partnership has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 47,367 shares. Sg Americas Secs Limited Liability Company invested in 26,990 shares.

Since September 18, 2017, it had 0 insider purchases, and 1 sale for $294,035 activity. The insider Cohen Fred E sold $294,035.

Analysts await BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to report earnings on February, 26. They expect $-0.14 earnings per share, down 133.33% or $0.08 from last year’s $-0.06 per share. After $-0.18 actual earnings per share reported by BioCryst Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -22.22% EPS growth.

Among 14 analysts covering BioCryst Pharmaceuticals (NASDAQ:BCRX), 12 have Buy rating, 0 Sell and 2 Hold. Therefore 86% are positive. BioCryst Pharmaceuticals had 34 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) earned “Buy” rating by H.C. Wainwright on Friday, May 26. H.C. Wainwright maintained the shares of BCRX in report on Tuesday, January 23 with “Buy” rating. The firm has “Hold” rating by RBC Capital Markets given on Thursday, November 2. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has “Overweight” rating given on Friday, August 12 by PiperJaffray. The stock has “Buy” rating by Jefferies on Wednesday, January 6. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, November 8 report. The stock has “Buy” rating by H.C. Wainwright on Tuesday, August 8. The stock has “Outperform” rating by RBC Capital Markets on Tuesday, January 2. The company was maintained on Friday, May 26 by Noble Financial. The rating was downgraded by Jefferies on Tuesday, February 9 to “Buy”.

Analysts await MGP Ingredients, Inc. (NASDAQ:MGPI) to report earnings on March, 1 before the open. They expect $0.49 EPS, up 2.08% or $0.01 from last year’s $0.48 per share. MGPI’s profit will be $8.19 million for 44.21 P/E if the $0.49 EPS becomes a reality. After $0.38 actual EPS reported by MGP Ingredients, Inc. for the previous quarter, Wall Street now forecasts 28.95% EPS growth.

Among 3 analysts covering MGP Ingredients (NASDAQ:MGPI), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. MGP Ingredients had 5 analyst reports since May 25, 2016 according to SRatingsIntel. On Monday, January 29 the stock rating was maintained by Craig Hallum with “Buy”. The rating was upgraded by Sidoti to “Buy” on Wednesday, January 31. The rating was initiated by Craig Hallum with “Buy” on Wednesday, May 25. The company was initiated on Wednesday, February 1 by Sidoti.

Since August 30, 2017, it had 0 insider buys, and 3 insider sales for $1.87 million activity. The insider Seaberg Karen sold $339,658.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.